<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-RJNKITXS/a99d383c-8d83-4c72-94e3-3da1b572fad7/PDF"><dcterms:extent>161 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-RJNKITXS/3db532a1-1815-49f5-8258-5779a83dccee/TEXT"><dcterms:extent>23 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="2022-2025"><edm:begin xml:lang="en">2022</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:DOC-RJNKITXS"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-UCB4A42Q" /><dcterms:issued>2025</dcterms:issued><dc:creator>Lešnik, Kaja</dc:creator><dc:creator>Slomšek, Ana</dc:creator><dc:format xml:lang="sl">številka:4</dc:format><dc:format xml:lang="sl">str. 55-58</dc:format><dc:identifier>COBISSID_HOST:248525059</dc:identifier><dc:identifier>ISSN:2820-5014</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-RJNKITXS</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Fakulteta za farmacijo, ŠSSFD</dc:publisher><dcterms:isPartOf xml:lang="sl">Placebo</dcterms:isPartOf><dc:subject xml:lang="en">acne</dc:subject><dc:subject xml:lang="sl">akne</dc:subject><dc:subject xml:lang="en">biological drugs</dc:subject><dc:subject xml:lang="en">biological molecule inhibitors</dc:subject><dc:subject xml:lang="sl">Biološka zdravila</dc:subject><dc:subject xml:lang="en">genetic engineering</dc:subject><dc:subject xml:lang="sl">Genska terapija</dc:subject><dc:subject xml:lang="sl">gensko inženirstvo</dc:subject><dc:subject xml:lang="sl">matične celice</dc:subject><dc:subject xml:lang="en">multifactorial pathophysiology</dc:subject><dc:subject xml:lang="en">stem cell therapy</dc:subject><dc:subject xml:lang="sl">večfaktorska patofiziologija</dc:subject><dc:subject xml:lang="sl">zaviralci bioloških molekul</dc:subject><dcterms:temporal rdf:resource="2022-2025" /><dc:title xml:lang="sl">Biološka zdravila za zdravljenje hormonalnih aken| različni pristopi zdravljenja dermatoveneroloških bolezni|</dc:title><dc:description xml:lang="sl">Acne is, especially among adolescents and young adults, a widespread dermatological condition with a multifactorial pathogenesis. The desire for more effective therapeutic outcomes with fewer side effects is driving improvements in existing treatment approaches, as well as the development of entirely new ones. The development of modern biological and biotechnological therapies is based on a thorough understanding of disease pathogenesis, which enables action on specific therapeutic targets. Antibodies that inhibit certain acne-related factors such as certain cytokines and enzymes are commonly used, but most of these biological drugs are off-label, meaning they are not registered for this indication. The potential of using genetic engineering for the purpose of delivering the active substance to the site of inflammation and stem cells to limit the inflammatory response is also being explored</dc:description><dc:description xml:lang="sl">Akne so predvsem pri mladostnikih in mladih odraslih pogosto dermatološko stanje z izrazito večfaktorsko patofiziologijo. Želja po učinkovitejših terapijah z manj neželenih učinkov spodbuja izboljšanje dosedanjih in vodi v razvoj novih terapevtskih pristopov. Razvoj sodobnih bioloških zdravil je osnovan na dobrem poznavanju mehanizmov nastanka bolezni, kar omogoča njihovo usmerjeno delovanje na specifične terapevtske tarče. Pogosta je uporaba protiteles, ki zavirajo določene dejavnike, povezane z razvojem aken, kot so nekateri citokini in encimi, vendar je njihova uporaba večinoma nenamenska, torej niso registrirana za to indikacijo. Raziskuje se tudi potencial uporabe genskega inženiringa za namene dostave zdravilne učinkovine na mesto vnetja in matičnih celic za omejitev vnetnega odziva</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:DOC-RJNKITXS"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:DOC-RJNKITXS" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:DOC-RJNKITXS/a99d383c-8d83-4c72-94e3-3da1b572fad7/PDF" /><edm:rights rdf:resource="http://rightsstatements.org/vocab/InC/1.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:dataProvider xml:lang="en">National and University Library of Slovenia</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:DOC-RJNKITXS/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:DOC-RJNKITXS" /></ore:Aggregation></rdf:RDF>